Olivia Vizier

A Network And Pivot Model For Success In Cancer Drug Development

When CEO Avanish Vellanki founded and incorporated Rain Therapeutics on his living room couch in the spring of 2017, there was no drug in development, no money, and a team of only four people. Five years later, after halting the development of its first licensed product, the Newark, CA-based precision oncology company awaits topline results

A Network And Pivot Model For Success In Cancer Drug Development Read More »

opthalmology times

MEIRAGTX ANNOUNCES DATA FROM PHASE 1/2 CLINICAL STUDY OF GENE THERAPY FOR PATIENTS WITH X-LINKED RETINITIS PIGMENTOSA

MeiraGTx today announced top-line data from the Phase 1/2 clinical study MGT009 (NCT03252847) of botaretigene sparoparvovec (formerly referred to as AAV-RPGR), an investigational gene therapy in development for the treatment of patients with X-linked retinitis pigmentosa (XLRP) with disease-causing variants in the RPGR gene.

MEIRAGTX ANNOUNCES DATA FROM PHASE 1/2 CLINICAL STUDY OF GENE THERAPY FOR PATIENTS WITH X-LINKED RETINITIS PIGMENTOSA Read More »

biospace

RAIN TARGETS NORMAL P53 EXPRESSION WITH POSSIBLE PAN-CANCER THERAPEUTIC

Rather than target mutated p53, Rain Therapeutics is looking at normal p53 expression as part of its novel mouse double minute 2 homolog (MDM2) inhibitor therapy. In the coming 12 months, Rain expects to have an interim readout for a Phase II study of its liposarcoma therapy, called milademetan (Rain-32), and a pivotal readout for its Phase III trial

RAIN TARGETS NORMAL P53 EXPRESSION WITH POSSIBLE PAN-CANCER THERAPEUTIC Read More »

empowered

Developing DNA Gene Therapies to Treat Chronic Inflammatory Diseases with Dr. Diem Nguyen Xalud Therapeutics

Dr. Diem Nguyen is the CEO of Xalud Therapeutics, a DNA delivery gene therapy company striving to develop and deliver medicines for large, broad-based disease indications like chronic inflammatory diseases, particularly musculoskeletal diseases like osteoarthritis of the knee and as well as neurodegenerative diseases like MS and ALS. Earlier in her career, Diem was the global

Developing DNA Gene Therapies to Treat Chronic Inflammatory Diseases with Dr. Diem Nguyen Xalud Therapeutics Read More »

diabetes-connections

“This is Becoming a Reality” – Sernova’s Cell Therapy Approach to a Functional T1D Cure

Big news from Sernova, one of the companies hoping that implantable stem cells will be a functional cure for diabetes. They recently announced that the first person in their trials with type 1 is completely off injected or infused insulin – and is making their own.

“This is Becoming a Reality” – Sernova’s Cell Therapy Approach to a Functional T1D Cure Read More »

real-world effectvieness of g-csf In pts with bc

Douglas W. Blayney, MD, FASCO, Clinical researcher and breast oncologist, Professor of Medicine at Stanford University. In this video, he speaks about the ASCO 2022 Abstract – Real-world effectiveness of prophylactic granulocyte colony-stimulating factor (G-CSF) early (week 1) and late (weeks 2-3) in the cycle for the prevention of febrile neutropenia (FN) among patients (pts)

real-world effectvieness of g-csf In pts with bc Read More »

pharma shots

PharmaShots Interview: In Conversation with Portage’s CEO and Director, Dr. Ian Walters, Where he Shares Insights on Ongoing Clinical-Stage and Development Programs

We are pleased with the progress made so far in our iNKT agonist programs and look forward to exploring these treatments further in future clinical trials. One recent collaboration that we announced was with Stanford University to explore the use of iNKT agonists with iNKT cell therapy.  

PharmaShots Interview: In Conversation with Portage’s CEO and Director, Dr. Ian Walters, Where he Shares Insights on Ongoing Clinical-Stage and Development Programs Read More »

biospace

Sernova Cell Pouch Keeps T1 Diabetes Patient Insulin Free for 2 Years

Sernova’s Cell Pouch is an implantable device that releases the primary donor islets. The device is implanted under the skin in a minimally-invasive procedure. At this time, Toleikis noted they are unsure of how long the device will continue to function and release the islets, which he said can read blood sugar levels and produce

Sernova Cell Pouch Keeps T1 Diabetes Patient Insulin Free for 2 Years Read More »

endpoints

Always chasing the newest science, Schond Greenway joins MindMed; Mirati fills key vacancy with ex-Arena finance chief

MindMed tapped Greenway as CFO on Monday, as CEO Robert Barrow guides the company through what he called “an exciting point in our growth.” The New York-based psychedelics company was the second to ever go public on an American exchange, behind Compass Pathways. And this year, Barrow’s lining up “numerous near-term milestones ahead across our

Always chasing the newest science, Schond Greenway joins MindMed; Mirati fills key vacancy with ex-Arena finance chief Read More »